Guangdong-based pharmaceutical manufacturer selling generic and specialty drugs in China.
Guangdong-based pharmaceutical manufacturer selling generic and specialty drugs in China.
Moat: none
Headquarters: Guangdong, China · Employees: 1,154
Size Guangdong Taienkang Pharmaceutical (301263.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.30B, the 1733rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.11 on 18 Nov 2026.
Performance Over six months the shares fell 23.7%, against -15.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 1.8% over the last twelve months (peer median +9.2%); the operating margin is -2.1% (peer median 2.8%).
Valuation It trades at 60.7× forward earnings against a peer median of 18.2× (3rd most expensive of 11).
Capital Return on invested capital runs 6.6 points below its cost of capital (8.3% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥682M | CN¥670M | CN¥711M | CN¥755M | CN¥779M |
| Revenue growth | — | -6% | -6% | -3% | — |
| Gross profit | CN¥407M | CN¥325M | CN¥371M | CN¥430M | CN¥434M |
| EBITDA | n/a | CN¥67.2M | CN¥159M | CN¥219M | CN¥225M |
| Net income | CN¥28.7M | CN¥28.6M | CN¥108M | CN¥160M | CN¥175M |
| Free cash flow | -CN¥11.0M | -CN¥119M | CN¥25.3M | -CN¥97.9M | CN¥68.3M |
| Capital expenditure | CN¥140M | CN¥108M | CN¥68.6M | CN¥200M | CN¥89.9M |
| Total debt | CN¥617M | CN¥366M | CN¥247M | CN¥176M | CN¥23.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301263.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -4.3% | 6th lowest of 20 |
| 6-month return | -23.7% | -15.6% | 7th lowest of 20 |
| Distance from 52-week high | -42.5% | -35.8% | 7th lowest of 20 |
| Revenue growth (TTM) | +1.8% | +9.2% | 6th lowest of 16 |
| Operating margin | -2.1% | 2.8% | 6th lowest of 16 |
| Forward P/E | 60.7× | 18.2× | 3rd most expensive of 11 |
| ROIC minus cost of capital | -6.6 pp | -3.3 pp | 6th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |